Zobrazeno 1 - 9
of 9
pro vyhledávání: '"D. M. Kweekel"'
Autor:
A C, Dijkmans, D M, Kweekel, C, Balmforth, M J, van Esdonk, J T, van Dissel, J, Burggraaf, I M C, Kamerling
Publikováno v:
The Netherlands journal of medicine. 77(7)
The preferred treatment for severe methicillin-sensitive Staphylococcus aureus infections is flucloxacillin, a small-spectrum antibiotic administered intravenously (IV) and orally. However, clinicians switch to the less preferred broad-spectrum antib
Autor:
Sasja F. Mulder, David M. Burger, D. M. Kweekel, Nienke A G Lankheet, Winette T. A. van der Graaf, Carla M.L. van Herpen, Ingrid M.E. Desar, Nielka P. van Erp
Publikováno v:
British Journal of Clinical Pharmacology. 83:2195-2204
AIM Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been established, which supports the rationale
Autor:
Jaap T. van Dissel, Jacobus Burggraaf, D. M. Kweekel, Ingrid M C Kamerling, Michiel J van Esdonk, Anneke C. Dijkmans
Publikováno v:
Antibiotics
Antibiotics, Vol 8, Iss 3, p 119 (2019)
Antibiotics, Vol 8, Iss 3, p 119 (2019)
Severe streptococcal infections are commonly treated with intravenous followed by oral penicillin (pheneticillin) therapy. However, switching from iv to oral therapy is complicated by the variability in oral pheneticillin absorption. We employed an O
Autor:
Henk-Jan Guchelaar, Ninja Antonini, Cornelis J. A. Punt, Hans Gelderblom, D. M. Kweekel, J.W.R. Nortier
Publikováno v:
British Journal of Cancer
British journal of cancer, 101(2), 357-362. Nature Publishing Group
British Journal of Cancer, 101, 2, pp. 357-62
British Journal of Cancer, 101, 357-62
British journal of cancer, 101(2), 357-362. Nature Publishing Group
British Journal of Cancer, 101, 2, pp. 357-62
British Journal of Cancer, 101, 357-62
Item does not contain fulltext PURPOSE: To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colore
Autor:
Henk-Jan Guchelaar, Tahar van der Straaten, D. M. Kweekel, Judith M. Vletter Bogaartz, Marco Tiller
Publikováno v:
The Journal of Molecular Diagnostics. 8:444-448
DNA repair enzymes play a pivotal role in platinum-based chemotherapy. Within the gene encoding for the base excision repair enzyme XRCC1, several nonsynonymous polymorphisms have been identified. It has been shown that the Arg399Gln single-nucleotid
Publikováno v:
Cancer Treatment Reviews. 31:90-105
Oxaliplatin is a relatively new platinum analogue that is currently used in pharmacotherapy of metastatic colorectal cancer. Its dose-limiting toxicity is sensory neuropathy, which can be modulated by infusion of calcium and magnesium. Oxaliplatin ex
Autor:
Henk-Jan Guchelaar, D. M. Kweekel, Kees Punt, Lieke H. van Huis-Tanja, Tahar van der Straaten, Hans Gelderblom, Miriam Koopman
Publikováno v:
Pharmacogenomics, 14(16), 2005-2012
Pharmacogenomics, 14(16), 2005-2012. Future Medicine Ltd.
Pharmacogenomics, 14(16), 2005-2012. Future Medicine Ltd.
Background & aim: Results from different pharmacogenetic association studies in colorectal cancer are often conflicting. Both peripheral blood and formalin-fixed, paraffin-embedded (FFPE) tissue are routinely used as DNA source. This could cause bias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::210367676aeaaa43fcdad478de643e12
http://hdl.handle.net/1887/101382
http://hdl.handle.net/1887/101382
Publikováno v:
Cancer treatment reviews. 34(7)
Irinotecan is a topo-isomerase-I inhibitor with broad antitumor activity in solid tumors. Its use may lead to severe toxicities, predominantly neutropenia and diarrhea which can be life-threatening. This review discusses clinical determinants and pha
Autor:
Henk-Jan Guchelaar, T. van der Straaten, C.J.A. Punt, M. Koopman, D. M. Kweekel, Hans Gelderblom, Ninja Antonini, J.W.R. Nortier
Publikováno v:
British Journal of Cancer, 99, 1316-21
British journal of cancer, 99(8), 1316-1321. Nature Publishing Group
British Journal of Cancer, 99, 8, pp. 1316-21
British Journal of Cancer
British journal of cancer, 99(8), 1316-1321. Nature Publishing Group
British Journal of Cancer, 99, 8, pp. 1316-21
British Journal of Cancer
Item does not contain fulltext A Valine residue at position 105 of the GSTP1 protein results in decreased enzyme activity. As nuclear GSTP1 activity decreases irinotecan cytotoxicity, Val-allele carriers may benefit more from irinotecan chemotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e619a86e0fa7905baf26391d68f249b
http://hdl.handle.net/2066/70208
http://hdl.handle.net/2066/70208